METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill-chemo combo takes on hard-to-treat cancers
Disease control Not yet recruitingThis study tests a new drug called SX-682 (a tablet) combined with the chemotherapy docetaxel in people whose head/neck, salivary gland, or prostate cancer has spread or returned after treatment. The goal is to find the right dose and see if the combination shrinks tumors. About …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Not yet recruitingThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new drug combo slow advanced prostate cancer?
Disease control Not yet recruitingThis trial is investigating whether an experimental drug called XNW5004, when combined with standard anti-tumor therapies, can help control advanced prostate cancer. The study involves men with prostate cancer that has spread. Researchers are looking at how safe the combination i…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New hope for hard-to-treat prostate cancer: drug combo trial launches
Disease control Not yet recruitingThis study tests a new drug combination (BL-B01D1 plus other treatments) in 180 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to hormone therapy. The goal is to see if the combination can delay cancer growth or shrink tumors. Part…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2, PHASE3 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Real-World data may reveal Pluvicto's true impact on advanced prostate cancer survival
Disease control Not yet recruitingThis study looks at how effective the drug Pluvicto (177Lu-PSMA-617) is in treating men with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to other parts of the body. Researchers will analyze medical records from over 1,000 patients …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Smart missile drug takes aim at Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new drug called DEC003M, which is designed to seek out and destroy prostate cancer cells by targeting a protein called PSMA. The trial enrolls adults with advanced prostate cancer that has stopped responding to standard hormone therapy. Researchers aim to find …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radioactive therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis phase 2 trial tests a radioactive drug called terbium-161 PSMA in 60 men with metastatic prostate cancer that has worsened after standard treatments. The drug is designed to seek out and destroy cancer cells. Participants will receive three cycles of the drug, and researcher…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Ankara University • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New drug QLC5508 takes on chemo in prostate cancer battle
Disease control Not yet recruitingThis Phase 3 trial compares an experimental drug, QLC5508, against the standard chemotherapy docetaxel in 700 men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy. The main goal is to see if QLC5508 delays cancer growth better than doce…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New drug QLF4113 enters first human tests for tough prostate cancer
Disease control Not yet recruitingThis early-stage trial tests a new drug, QLF4113, in about 140 men with metastatic castration-resistant prostate cancer that has spread and no longer responds to standard hormone therapy. The main goals are to find a safe dose and check for side effects, while also looking for si…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for prostate cancer: drug combo aims to delay tumor growth
Disease control Not yet recruitingThis study tests a daily pill called zanzalintinib in men with advanced prostate cancer that has stopped responding to hormone therapy and has already been treated with Pluvicto. The goal is to see if the drug can delay cancer growth or shrinkage. About 30 participants will take …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Stuthi Perimbeti • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for Hard-to-Treat prostate cancer: experimental drug zanzalitinib under study
Disease control Not yet recruitingThis study tests a new drug called zanzalitinib in people with a type of advanced prostate cancer that no longer responds to hormone therapy and has spread to soft tissues or organs. The goal is to see if the drug can slow or stop cancer growth. About 19 participants will receive…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Pedro Barata, MD, MSc • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis early-stage trial tests a combination of two drugs—docetaxel (chemotherapy) and a radioactive compound called 177Lu-PSMA-I&T—in men with advanced prostate cancer that no longer responds to hormone therapy. The goal is to find the safest dose of docetaxel when used with the r…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for tough prostate cancer? drug trial targets resistant tumors
Disease control Not yet recruitingThis phase 2 trial tests an oral drug called pacritinib in 32 men with metastatic castrate-resistant prostate cancer that has worsened after standard treatments. The drug is taken twice daily, and the main goal is to see if it can delay cancer growth for at least six months. Part…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis early-stage trial tests a new radioactive drug called 177Lu-FC516 in 13 men with advanced prostate cancer that has stopped responding to standard treatments. The drug is given every 6 weeks for up to 4 cycles. The main goals are to find the safest dose and check for side eff…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Double radiation attack aims to stop prostate cancer bone breaks
Disease control Not yet recruitingThis phase 2 trial tests whether adding precise external beam radiation to standard radioligand therapy can better control metastatic prostate cancer that no longer responds to hormone therapy. About 120 participants will receive either standard treatment alone or combined with t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New drug ITC-6146RO enters first human tests for tough cancers
Disease control Not yet recruitingThis early-phase trial tests an experimental drug called ITC-6146RO in about 102 adults with advanced or metastatic cancers (like prostate, lung, or breast cancer) that have not improved with standard treatments. The study has two parts: first, finding a safe dose, then checking …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: IntoCell, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New radioactive drug targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis early-phase study tests a new radioactive drug, 161Tb-LNC1011, in 15 men with advanced prostate cancer that no longer responds to hormone therapy. The drug is designed to seek out and deliver radiation directly to cancer cells. The main goals are to check safety and find the…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Experimental drug targets Low-Oxygen tumors in prostate cancer
Disease control Not yet recruitingThis phase 2 trial tests whether adding evofosfamide to standard hormone therapy can help men with castration-resistant prostate cancer that has spread. The drug targets low-oxygen areas in tumors. 35 participants will receive the drug combination and be monitored for PSA respons…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New pill takes on advanced cancers in early human trial
Disease control Not yet recruitingThis study tests an experimental oral drug called XNW34017 in 150 people with advanced solid tumors who have not responded to or cannot tolerate standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors. It is an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New Dual-Action therapy targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis study tests a new approach for men with advanced prostate cancer that no longer responds to hormone therapy. It uses a special imaging agent to find cancer cells and a radioactive drug to destroy them. The goal is to see if the treatment is safe and shrinks tumors. About 49 …
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Chengdu StarRay Therapeutics Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New hope for advanced prostate cancer: combination therapy enters human trials
Disease control Not yet recruitingThis early-stage trial tests the safety of combining a targeted radiation drug (lutetium DGUL) with an immunotherapy (pembrolizumab) in 30 men with metastatic castration-resistant prostate cancer. Participants receive either the radiation drug alone or both drugs together. The go…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Cellbion Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New pill targets Hard-to-Treat prostate cancer
Disease control Not yet recruitingThis trial tests an experimental oral drug called TQB3201 in people with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. The drug works by breaking down a key protein that fuels cancer growth, even in cancers with resistance mutat…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 17:15 UTC
-
A PET scan and a blood test may predict which men with advanced prostate cancer will benefit from targeted therapy
Diagnosis Not yet recruitingThis trial is testing whether a special PET scan (FTT-PET) and a blood test that looks for tumor DNA (ctDNA) can predict how well men with metastatic prostate cancer will respond to PARP inhibitor therapy. The study will enroll about 75 men whose cancers have certain genetic muta…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Washington University School of Medicine • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
New PET scans aim to spot prostate cancer more clearly
Diagnosis Not yet recruitingThis study tests three new radioactive imaging agents against a standard one for PET/CT scans in 9 men with advanced prostate cancer. The goal is to see which agent best highlights cancer lesions in the body. It is an early-stage imaging study, not a treatment trial.
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: NA • Sponsor: Shanghai Zhongshan Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 08:14 UTC
-
Could a simple MRI replace a PET scan for safer cancer radiation?
Knowledge-focused Not yet recruitingThis study will test whether a special MRI scan (CSE-MRI) can accurately measure active bone marrow in men with metastatic prostate cancer, compared to a standard PET scan using a radioactive tracer (FLT). Fifteen participants will receive both scans at the same time using a comb…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
New study tests if SPECT imaging can forecast prostate cancer treatment success
Knowledge-focused Not yet recruitingThis study will look at whether SPECT scans taken after Lu-PSMA therapy can help predict how well patients with metastatic castration-resistant prostate cancer (mCRPC) are doing. Researchers will measure tumor activity and volume on the scans and compare them to standard PET-base…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Sponsor: Central Hospital, Nancy, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC